Vol.61 No.4 July 2013
Evaluation of S-1+Oxaliplatin+Bevacizumab combination chemotherapy as neoadjuvant chemotherapy for patients with resectable liver metastases from colorectal cancer
Department of General Surgery, Toyohashi Municipal Hospital, 50 Hakken-Nishi, Aotake-cho, Toyohashi, Aichi, Japan
Abstract
Liver metastasis of colorectal cancer is one of the important prognostic factors for cancer treatment. Surgical resection for patients with colorectal liver metastases is currently considered the only potentially curative option for these patients. S-1, oxaliplatin and bevacizumab have been used as key drugs in the treatment of advanced colorectal cancer, but there has been no report on the feasibility and efficacy of these three drugs (SOX+BV) as neoadjuvant chemotherapy (NAC) for resectable colorectal liver metastases.
We report herein on 6 cases of SOX+BV as NAC for patients with resectable liver-only metastases from colorectal cancer and evaluate the safety and the short-term outcome of SOX+BV chemotherapy. Bevacizumab (7.5 mg/kg) and oxaliplatin (130 mg/m2) were administrated intravenously on day 1, whereas S-1 was administrated orally (80 mg/m2/day, b.i.d.) for 14 days followed by a 7-day rest. The overall response rate was 83.3% (CR, 1 patient; PR, 4 patients; SD, 1 patient) and disease control was 100% (6/6 patients). Grade 3/4 side effects were observed in 2 patients (1 patient each with neutropenia and diarrhea).
In this study, we perfomed R0 hepatectomy for all cases, and had no major complications. Our results suggest that preoperative SOX+BV chemotherapy for hepatectomy of metastatic colorectal cancer is safe and has no adverse effect on surgery. In future, further studies on SOX+BV chemotherapy, involving such factors as PFS, OS, and QOL, need to be addressed.
Key word
S-1, oxaliplatin, bevacizumab, neoadjuvant chemotherapy, colorectal cancer
Received
February 14, 2013
Accepted
April 16, 2013
Jpn. J. Chemother. 61 (4): 343-346, 2013
